Allergan Moved on with Heptares Therapeutics After the Breakup with Pfizer Inc.
Only a day after that Pfizer–Allergan deal was officially terminated, Allegan is ready with a potential $3.3 billion collaboration with Heptares for the development of portfolio against Alzheimer’s disease.
Allergan (Dublin, Ireland) collaborated with Heptares Therapeutics (Hertfordshire, UK), a wholly owned subsidiary of Sosei Group Corporation (Japan) under the $3.3 billion licence agreement for its Alzheimer disease portfolio. Under the agreement Allergan will get the exclusive global rights to the novel subtype– selective muscarinic receptor agonists which are G-protein coupled receptors (GPCRs) found in cell membranes of various neurons and other cells. They are under development for treatment of various neurological disorders like Alzheimer. The deal encompasses selective M1, M4 muscarinic receptors along with dual M1/M4 agonists, including HTL9936 and HTL18318. M1 selective compounds are for symptomatic treatment of cognitive impairment while M4 selective compound are for ameliorating neurobehavioral symptoms.
The collaboration came up as a great restitution for Allergan after a $160 billion merger between Allergan and US based Pfizer was terminated over a new temporary regulations on tax inversion in US. Pfizer will pay $150 million to Allergan as a reimbursement for the expenses related to the termination of the deal.
The deal between the Allergan and Heptares will fetch the later company an upfront payment of $125 million and future milestone payment of around $665 million associated with the successful phase trials and launch of first three licensed compounds . Apart from it Heptares will receive approximately $2.5 billion related to the future sales of the launched product. It will receive royalties on the net sales of all the compound falling under the partnership.
Allergan will also sponsor the coming research and development program of upto $50 million that will be jointly conducted by Allergan and Heptares regarding Phase II clinical trials.
Malcolm Weir, Chief Executive Officer of Heptares and Chief R&D Officer at Sosei, said: “We are delighted that the quality of our muscarinic agonist candidates, discovered and developed wholly in-house, and our translational capabilities have been recognized by Allergan, a global leader in the development and commercialization of treatments for CNS diseases. We have a highly committed and experienced partner in Allergan and look forward to working together towards the development of multiple new breakthrough medicines over the coming years.”
Alzheimer’s disease (AD) is a gradually progressive neurodegenerative disorder which is characterized by loss of memory and cognitive functions. It usually develops during 50s but it may occur at an early age which could be a rare case. In past few years it has become prevalent in almost every corner of the world. As such no permanent cure for Alzheimer’s is available but some kind of drug therapies are available for symptomatic treatment. Till date two kinds of drug are used for treatment of Alzheimer’s: acetylcholinesterase inhibitors and NMDA receptor antagonists.
Heptares Therapeutics is a clinical stage company focused primarily on the development of medicines targeting GPCRs which is a family of receptors associated to broad range of diseases.
Allergan Inc. is a global pharmaceutical company focused on the development, manufacturing and marketing of medicines for CNS, eye care, medical dermatology, gastroenterology, women’s health, urology, cardiovascular, neurosciences and anti-infective therapeutic categories.
Featured image credit: Perfect Business Partnership © digitalista (Stock Photo ID: 114894110)